Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAXXITEK HVT + IBD + H5
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- In Ovo, Subcutaneous
01
Overview
VAXXITEK HVT + IBD + H5 is a trivalent recombinant vector vaccine developed for poultry, providing protection against three major avian diseases: Marek’s disease, Infectious Bursal Disease (IBD), and highly pathogenic avian influenza caused by the H5 subtype. The vaccine uses a live recombinant herpesvirus of turkeys (HVT) as a vector to express two protective antigens: the VP2 protein from Infectious Bursal Disease Virus (IBDV) and the hemagglutinin (HA) gene from the avian influenza virus subtype H5. The HA gene is designed using COBRA technology to provide broad cross-clade protection against multiple circulating strains of the highly pathogenic avian influenza virus. Administered at hatcheries either in ovo or to day-old chicks, this single-shot vaccine induces early immunity and helps avoid gaps between waning maternal antibodies and active immune response. It also functions as a DIVA (Differentiating Infected from Vaccinated Animals) vaccine, enabling effective disease surveillance during outbreaks[1][4][6][7].
- Brand names
- VAXXITEK HVT+IBD+H5
- Other names
- VAXXITEK HVT+IBD+AIV-H5trivalent recombinant HVT vaccine (contextual/technical)
02
Targets
BCR (Immunoglobulin G B Cell Receptor)Meleagrid alphaherpesvirus 1 entry receptorsH5 HA (Influenza A hemagglutinin H5)VP2 (Infectious bursal disease virus VP2 protein)
Beyond the preview
Go deeper on VAXXITEK HVT + IBD + H5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAXXITEK HVT + IBD + H5.